Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes

Activity of a New Cephalosporin, CXA-101 (FR264205), against  -Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients

(2010) B. Moya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions

(2010) Y. Ge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus  -lactamase-producing Enterobacteriaceae

(2010) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antimicrobial Susceptibility Patterns of KPC-Producing or CTX-M-Producing Enterobacteriaceae

(2010) Mariana Castanheira et al.   Microbial Drug Resistance

In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance

(2009) C. C. Bulik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical Strains

(2009) C. Juan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates

(2009) David M. Livermore et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS